Still, it is clear that GLP-1 new drug treatments like tirzepatide (sold as Mounjaro for diabetes and ZepBound for obesity by Eli Lilly, and as Mounjaro/ZepBound for weight management) and semaglutide (Wegovy/Ozempic by Novo Nordisk) are among the fastest-growing and highest-earning drugs on the planet
4.3.1 Multi-target approach in polycystic ovary syndrome Polycystic ovary syndrome (PCOS) represents a complex endocrine-metabolic disorder characterized by a vicious cycle between insulin resistance and oxidative stress (231, 232)
Both are FDA-approved with overlapping safety profiles, and the shared warnings (thyroid, pancreatitis, gallbladder) apply equally to each
GSH has long been implicated as a major antioxidant and redox regulator that functions to mitigate and alleviate this oxidative damage ( However, the preceding sections of this paper establish that GSH is not merely a passive antioxidant, but an immune regulator and modulator with actions dependent upon the pathophysiologic context (Ghezzi, 2011) GSH acts to regulate the thresholds necessary for immunologic activation through redox-sensitive signal transduction pathways, influences antigen presentation and the development/differentiation of immune cells, and modulates the production of cytokines
Whats clear is that competition will reshape the landscape
The high cost of GLP-1 RAs may create a system where effective obesity treatment is available only to those with adequate insurance coverage or financial resources